This page shows the latest SMA news and features for those working in and with pharma, biotech and healthcare.
added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene
It will be conducted at around 20 sites globally, with researchers aiming to enrol up to 60 children with SMA. ... to develop SMA type 1, and who were six months old or younger when they received Zolgensma.
Novartis’ main growth drivers, and protectors against the continuing impact caused by the COVID-19 pandemic, includes its spinal muscular atrophy (SMA) gene therapy Zolgensma and chronic heart failure med Entresto
In addition, some of the research undertaken at AskBio was used to in the development of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma.
SMA is a muscle-wasting disease that affects around one in 6, 000 to 10, 000 live births and is a leading cause of genetic death in infants. ... The first drug to reach the market for SMA was Biogen’s Spinraza (nusinersen) back in 2016.
Both companies are facing upcoming competition from Roche’s rival drug risdiplam, which has scored an FDA priority review in SMA. ... Roche is also currently investigating risdiplam in an additional clinical trial in infants with SMA type 1.
More from news
Approximately 17 fully matching, plus 57 partially matching documents found.
Vision for the future. As we look forward, sustainability will continue to influence company strategies, particularly given that some new drugs, such as Zolgensma for spinal muscular atrophy (SMA), cost US$2m
the genetic defect underlying spinal muscular atrophy (SMA). ... In the third quarter of 2018, AveXis filed Zolgensma for approval in the US, EU and Japan for the treatment of SMA type I.
Bluebird is not the only company likely to break through this 1m barrier in 2019 – Novartis’ SMA gene therapy Zolgensma is also on the cusp of approval in the US.
The next step in this process is the launch of Zolgensma (AveXis) – the gene therapy for spinal muscular atrophy (SMA) which is now filed with the FDA and EMA, and is ... The company argues that current ten- year costs of caring for SMA type 1 patients
And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to the health of motor
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
He has also served as a global consultant for Roche, scientific adviser to Vertex and Ariad, and currently sits on the boards of the US National Cancer Institute and the SMA
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
All eyes on Spinraza. Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil? ... In April 2019, Brazilian Health Minister Luiz Henrique
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...